Proliferative Vitreoretinopathy Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2032

8.56%
CAGR (2026-2032)
1.82 USD Bn.
Market Size
308
Report Pages
156
Market Tables

Overview

Global Orthopedic Bone Cement and Casting Material Market size was valued at USD 760.92 Mn. in 2025, and the total Gas Turbine revenue is expected to grow at a CAGR of 5.30% from 2026 to 2032, reaching nearly USD 1092.29 Mn. by 2032.

Global Proliferative Vitreoretinopathy Market Definition

Proliferative vitreoretinopathy is a disease process that follows the proliferation of ectopic cell sheets in the vitreous and/or perirenal area, causing epiretinal membrane formation and traction, in patients with rhegmatogenous retinal detachments.
The report covers the current estimated and forecasted data for the Global Proliferative Vitreoretinopathy Market on a global and regional level. The report provides an in-depth analysis of the Global Proliferative Vitreoretinopathy Market for the period 2025 – 2032, wherein 2025 is the base year and the period from 2026 – 2032 is the forecast period.

The report provides qualitative and quantitative insights on the Proliferative Vitreoretinopathy industry trends and a detailed analysis of market size and growth rate of all segments in the market. The Global Proliferative Vitreoretinopathy Market is segmented by End-User and Region.

Global Proliferative Vitreoretinopathy Market Dynamics

According to the research conducted by the Retina Society Terminology committee, there is 5%-10% progress in proliferative vitreoretinopathy every year.
Consideration of pathobiological effects of PVR and identification of risk factors are increasing the successful operation rate of PVR. The adoption of endolaser applications in the PVR and standard surgical procedures are driving the global market. Tremendous advances in surgical techniques and technology in the ophthalmology field are propelling the global proliferative vitreoretinopathy market. The Increasing Prevalence of patients having retinoblastoma is driving the global market.

Global Proliferative Vitreoretinopathy Market Segment Analysis – by End-User

Global Proliferative Vitreoretinopathy Market

To know about the Research Methodology :- Request Free Sample Report

Hospitals commanded the largest market share of xx% in the global proliferative vitreoretinopathy market.

Testing of different drugs and drug-delivery systems for the vitreoretinopathy enhance the hospital treatment procedures of vitreoretinopathy. The occurrence of PVR in up to 50% of peoples who have had an open globe injury is boosting the global market. Innovation of new surgeries in retinal surgery and adoption of techniques in the operation procedures are driving the global vitreoretinopathy market.

Global Proliferative Vitreoretinopathy Market Regional Analysis

Global Proliferative Vitreoretinopathy Market

North America contributes the largest share for the growth of the global proliferative vitreoretinopathy market.

The ongoing research & development activities by the government and private research organizations are expected to project the global market in the forecast period. The growing interest of scientists in the findings of targeted therapeutics for vitreoretinopathy is resulting in the improvement of treatment and curation. Adoption of medical devices in the retinal operation procedure commended the largest market share of xx% in the global market.

The objective of the report is to present a comprehensive analysis of the global proliferative vitreoretinopathy market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the global proliferative vitreoretinopathy market dynamics, structure by analyzing the market segments and project the global proliferative vitreoretinopathy market clear representation of competitive analysis of key players by price, financial position, by detection and equipment portfolio, growth strategies, and regional presence in the global proliferative vitreoretinopathy market make the report investor’s guide.

Global Aeromonads Diagnostic Testing Market Recent Developments:

Exact Date Company Development Impact
17 March 2026 Aldeyra Therapeutics Aldeyra reported its intent to shift focus toward ADX-2191 (intravitreal methotrexate) for rare retinal diseases following a Complete Response Letter (CRL) for its dry eye candidate. This strategic reallocation of R&D resources aims to accelerate the development of ADX-2191 as a potential first-in-class treatment for preventing proliferative vitreoretinopathy.
25 February 2026 Veeva Clinical Trials A new clinical trial was registered to evaluate the safety and efficacy of intravitreal topotecan specifically for patients with rhegmatogenous retinal detachment due to PVR. The study investigates topotecan’s anti-proliferative activity as a possible pharmacological adjuvant to vitrectomy, targeting a reduction in post-surgical recurrence rates.
19 February 2026 Apellis Pharmaceuticals Apellis presented five-year safety data from the GALE extension study, monitoring patients for adverse events including retinal detachment and PVR following complement inhibition. Long-term safety profiles for intravitreal therapies are vital for establishing risk-benefit ratios in chronic retinal management where PVR remains a severe complication.
08 February 2026 ResearchGate / Int Ophthalmol A comprehensive review identified methotrexate and infliximab as the most promising candidates for pharmacological modulation of PVR in high-risk populations. The analysis provides a standardized protocol framework for future randomized trials, emphasizing the transition from purely surgical management to adjunctive molecular therapy.
28 August 2025 Aldeyra Therapeutics Aldeyra received Orphan Designation from the European Medicines Agency (EMA) for ADX-2191 for treating primary large B-cell lymphomas and related retinal diseases. The designation grants ten years of market exclusivity in the EU, significantly boosting the commercial valuation of the vitreous-compatible methotrexate formulation.
19 August 2025 Aldeyra Therapeutics The U.S. FDA granted Fast Track Designation to ADX-2191 to expedite the review of treatments for rare genetic retinal diseases. This regulatory milestone facilitates frequent communication with the FDA, potentially shortening the timeline for bringing PVR-prophylactic agents to the clinical market.

 

Global Aeromonads Diagnostic Testing Market Report Scope: Inquire before buying

Global Proliferative Vitreoretinopathy Market
Report Coverage Details
Base Year: 2025 Forecast Period: 2026-2032
Historical Data: 2020 to 2025 Market Size in 2025: 1.82 USD Billion
Forecast Period 2026-2032 CAGR: 8.56% Market Size in 2032: 3.23 USD Billion
Segments Covered: by Type PRM‑167
XOMA‑089
Others
by End‑User Hospital
Clinic
Ambulatory Surgery Centers (ASCs)
Others

 

Global Proliferative Vitreoretinopathy Market, by Region

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America

Global Proliferative Vitreoretinopathy Market Key Players

  1. Novartis AG
  2. Regeneron Pharmaceuticals, Inc.
  3. Genentech, Inc.
  4. Pfizer, Inc.
  5. Allergan plc (AbbVie Inc.)
  6. Bausch + Lomb Corporation
  7. Promedior Inc.
  8. RXi Pharmaceuticals Corp
  9. Clearside Biomedical, Inc.
  10. Oxurion NV
  11. Adverum Biotechnologies, Inc.
  12. Aldeyra Therapeutics, Inc.
  13. Carl Zeiss Meditec AG
  14. HOYA Corporation
  15. Essilor International S.A.
  16. HAAG-Streit Holding AG
  17. Johnson & Johnson Vision
  18. Nidek Co. Ltd.
  19. Topcon Corporation
  20. Ziemer Ophthalmic Systems AG
  21. Hoffmann-La Roche Ltd
  22. Bayer AG
  23. Santen Pharmaceutical Co., Ltd.
  24. Alcon (Novartis/Independent)
  25. Intra-Cellular Therapies
  26. Regulus Therapeutics
  27. Kodiak Sciences
  28. Iveric Bio
  29. Aerpio Pharmaceuticals
  30. Apellis Pharmaceuticals

Others

Table of Contents

1. Global Proliferative Vitreoretinopathy Market Introduction
1.1. Study Assumption and Market Definition
1.2. Scope of the Study
1.3. Executive Summary
2. Global Global Proliferative Vitreoretinopathy Market: Competitive Landscape
2.1. MMR Competition Matrix
2.2. Competitive Landscape
2.3. Key Players Benchmarking
2.3.1. Company Name
2.3.2. Business Segment
2.3.3. End-user Segment
2.3.4. Revenue (2025)
2.3.5. Company Locations
2.4. Leading Global Proliferative Vitreoretinopathy Market Companies, by market capitalization
2.5. Market Structure
2.5.1. Market Leaders
2.5.2. Market Followers
2.5.3. Emerging Players
2.6. Mergers and Acquisitions Details
3. Global Proliferative Vitreoretinopathy Market: Dynamics
3.1. Global Proliferative Vitreoretinopathy Market Trends by Region
3.1.1. North America Global Proliferative Vitreoretinopathy Market Trends
3.1.2. Europe Global Proliferative Vitreoretinopathy Market Trends
3.1.3. Asia Pacific Global Proliferative Vitreoretinopathy Market Trends
3.1.4. Middle East and Africa Global Proliferative Vitreoretinopathy Market Trends
3.1.5. South America Global Proliferative Vitreoretinopathy Market Trends
3.2. Global Proliferative Vitreoretinopathy Market Dynamics by Region
3.2.1. North America
3.2.1.1. North America Global Proliferative Vitreoretinopathy Market Drivers
3.2.1.2. North America Global Proliferative Vitreoretinopathy Market Restraints
3.2.1.3. North America Global Proliferative Vitreoretinopathy Market Opportunities
3.2.1.4. North America Global Proliferative Vitreoretinopathy Market Challenges
3.2.2. Europe
3.2.2.1. Europe Global Proliferative Vitreoretinopathy Market Drivers
3.2.2.2. Europe Global Proliferative Vitreoretinopathy Market Restraints
3.2.2.3. Europe Global Proliferative Vitreoretinopathy Market Opportunities
3.2.2.4. Europe Global Proliferative Vitreoretinopathy Market Challenges
3.2.3. Asia Pacific
3.2.3.1. Asia Pacific Global Proliferative Vitreoretinopathy Market Drivers
3.2.3.2. Asia Pacific Global Proliferative Vitreoretinopathy Market Restraints
3.2.3.3. Asia Pacific Global Proliferative Vitreoretinopathy Market Opportunities
3.2.3.4. Asia Pacific Global Proliferative Vitreoretinopathy Market Challenges
3.2.4. Middle East and Africa
3.2.4.1. Middle East and Africa Global Proliferative Vitreoretinopathy Market Drivers
3.2.4.2. Middle East and Africa Global Proliferative Vitreoretinopathy Market Restraints
3.2.4.3. Middle East and Africa Global Proliferative Vitreoretinopathy Market Opportunities
3.2.4.4. Middle East and Africa Global Proliferative Vitreoretinopathy Market Challenges
3.2.5. South America
3.2.5.1. South America Global Proliferative Vitreoretinopathy Market Drivers
3.2.5.2. South America Global Proliferative Vitreoretinopathy Market Restraints
3.2.5.3. South America Global Proliferative Vitreoretinopathy Market Opportunities
3.2.5.4. South America Global Proliferative Vitreoretinopathy Market Challenges
3.3. PORTER's Five Forces Analysis
3.4. PESTLE Analysis
3.5. Technology Roadmap
3.6. Regulatory Landscape by Region
3.6.1. North America
3.6.2. Europe
3.6.3. Asia Pacific
3.6.4. Middle East and Africa
3.6.5. South America
3.7. Key Opinion Leader Analysis For Global Proliferative Vitreoretinopathy Industry
3.8. Analysis of Government Schemes and Initiatives For Global Proliferative Vitreoretinopathy Industry
3.9. Global Proliferative Vitreoretinopathy Market Trade Analysis
3.10. The Global Pandemic Impact on Global Proliferative Vitreoretinopathy Market
4. Global Proliferative Vitreoretinopathy Market: Global Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
4.1. Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
4.1.1. PRM‑167
4.1.2. XOMA‑089
4.1.3. Others
4.2. Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
4.2.1. Hospital
4.2.2. Clinic
4.2.3. Ambulatory Surgery Centers (ASCs)
4.2.4. Others
4.3. Global Proliferative Vitreoretinopathy Market Size and Forecast, by Region (2025-2032)
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. Middle East and Africa
4.3.5. South America
5. North America Global Proliferative Vitreoretinopathy Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
5.1. North America Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
5.1.1. PRM‑167
5.1.2. XOMA‑089
5.1.3. Others
5.2. North America Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
5.2.1. Hospital
5.2.2. Clinic
5.2.3. Ambulatory Surgery Centers (ASCs)
5.2.4. Others
5.3. North America Global Proliferative Vitreoretinopathy Market Size and Forecast, by Country (2025-2032)
5.3.1. United States
5.3.1.1. United States Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
5.3.1.1.1. PRM‑167
5.3.1.1.2. XOMA‑089
5.3.1.1.3. Others
5.3.1.2. United States Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
5.3.1.2.1. Hospital
5.3.1.2.2. Clinic
5.3.1.2.3. Ambulatory Surgery Centers (ASCs)
5.3.1.2.4. Others
5.3.2. Canada
5.3.2.1. Canada Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
5.3.2.1.1. PRM‑167
5.3.2.1.2. XOMA‑089
5.3.2.1.3. Others
5.3.2.2. Canada Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
5.3.2.2.1. Hospital
5.3.2.2.2. Clinic
5.3.2.2.3. Ambulatory Surgery Centers (ASCs)
5.3.2.2.4. Others
5.3.3. Mexico
5.3.3.1. Mexico Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
5.3.3.1.1. PRM‑167
5.3.3.1.2. XOMA‑089
5.3.3.1.3. Others
5.3.3.2. Mexico Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
5.3.3.2.1. Hospital
5.3.3.2.2. Clinic
5.3.3.2.3. Ambulatory Surgery Centers (ASCs)
5.3.3.2.4. Others
6. Europe Global Proliferative Vitreoretinopathy Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
6.1. Europe Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.2. Europe Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3. Europe Global Proliferative Vitreoretinopathy Market Size and Forecast, by Country (2025-2032)
6.3.1. United Kingdom
6.3.1.1. United Kingdom Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.1.2. United Kingdom Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3.2. France
6.3.2.1. France Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.2.2. France Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3.3. Germany
6.3.3.1. Germany Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.3.2. Germany Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3.4. Italy
6.3.4.1. Italy Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.4.2. Italy Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3.5. Spain
6.3.5.1. Spain Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.5.2. Spain Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3.6. Sweden
6.3.6.1. Sweden Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.6.2. Sweden Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3.7. Austria
6.3.7.1. Austria Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.7.2. Austria Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
6.3.8. Rest of Europe
6.3.8.1. Rest of Europe Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
6.3.8.2. Rest of Europe Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7. Asia Pacific Global Proliferative Vitreoretinopathy Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
7.1. Asia Pacific Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.2. Asia Pacific Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3. Asia Pacific Global Proliferative Vitreoretinopathy Market Size and Forecast, by Country (2025-2032)
7.3.1. China
7.3.1.1. China Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.1.2. China Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.2. S Korea
7.3.2.1. S Korea Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.2.2. S Korea Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.3. Japan
7.3.3.1. Japan Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.3.2. Japan Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.4. India
7.3.4.1. India Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.4.2. India Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.5. Australia
7.3.5.1. Australia Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.5.2. Australia Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.6. Indonesia
7.3.6.1. Indonesia Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.6.2. Indonesia Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.7. Malaysia
7.3.7.1. Malaysia Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.7.2. Malaysia Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.8. Vietnam
7.3.8.1. Vietnam Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.8.2. Vietnam Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.9. Taiwan
7.3.9.1. Taiwan Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.9.2. Taiwan Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
7.3.10. Rest of Asia Pacific
7.3.10.1. Rest of Asia Pacific Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
7.3.10.2. Rest of Asia Pacific Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
8. Middle East and Africa Global Proliferative Vitreoretinopathy Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
8.1. Middle East and Africa Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
8.2. Middle East and Africa Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
8.3. Middle East and Africa Global Proliferative Vitreoretinopathy Market Size and Forecast, by Country (2025-2032)
8.3.1. South Africa
8.3.1.1. South Africa Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
8.3.1.2. South Africa Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
8.3.2. GCC
8.3.2.1. GCC Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
8.3.2.2. GCC Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
8.3.3. Nigeria
8.3.3.1. Nigeria Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
8.3.3.2. Nigeria Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
8.3.4. Rest of ME&A
8.3.4.1. Rest of ME&A Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
8.3.4.2. Rest of ME&A Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
9. South America Global Proliferative Vitreoretinopathy Market Size and Forecast by Segmentation (in USD Billion) 2025-2032
9.1. South America Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
9.2. South America Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
9.3. South America Global Proliferative Vitreoretinopathy Market Size and Forecast, by Country (2025-2032)
9.3.1. Brazil
9.3.1.1. Brazil Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
9.3.1.2. Brazil Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
9.3.2. Argentina
9.3.2.1. Argentina Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
9.3.2.2. Argentina Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
9.3.3. Rest Of South America
9.3.3.1. Rest Of South America Global Proliferative Vitreoretinopathy Market Size and Forecast, by Type (2025-2032)
9.3.3.2. Rest Of South America Global Proliferative Vitreoretinopathy Market Size and Forecast, by End‑User (2025-2032)
10. Company Profile: Key Players
10.1. Novartis AG
10.1.1. Company Overview
10.1.2. Business Portfolio
10.1.3. Financial Overview
10.1.4. SWOT Analysis
10.1.5. Strategic Analysis
10.1.6. Scale of Operation (small, medium, and large)
10.1.7. Details on Partnership
10.1.8. Regulatory Accreditations and Certifications Received by Them
10.1.9. Awards Received by the Firm
10.1.10. Recent Developments
10.2. Regeneron Pharmaceuticals
10.3. Inc.
10.4. Genentech
10.5. Pfizer
10.6. Allergan plc (AbbVie Inc.)
10.7. Bausch + Lomb Corporation
10.8. Promedior Inc.
10.9. RXi Pharmaceuticals Corp
10.10. Clearside Biomedical
10.11. Oxurion NV
10.12. Adverum Biotechnologies
10.13. Aldeyra Therapeutics
10.14. Carl Zeiss Meditec AG
10.15. HOYA Corporation
10.16. Essilor International S.A.
10.17. HAAG-Streit Holding AG
10.18. Johnson & Johnson Vision
10.19. Nidek Co. Ltd.
10.20. Topcon Corporation
10.21. Ziemer Ophthalmic Systems AG
10.22. F. Hoffmann-La Roche Ltd
10.23. Bayer AG
10.24. Santen Pharmaceutical Co.
10.25. Alcon (Novartis/Independent)
10.26. Intra-Cellular Therapies
10.27. Regulus Therapeutics
10.28. Kodiak Sciences
10.29. Iveric Bio
10.30. Aerpio Pharmaceuticals
10.31. Apellis Pharmaceuticals
11. Key Findings
12. Industry Recommendations
13. Global Proliferative Vitreoretinopathy Market: Research Methodology
14. Terms and Glossary

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Request Customization Download Sample